{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:45:55Z","timestamp":1793839555597,"version":"4.6.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":253,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI100805"],"award-info":[{"award-number":["U01AI100805"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI100805"],"award-info":[{"award-number":["U01AI100805"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Evaluation of optimal dosing has generally been inadequate during tuberculosis (TB) drug development. Fluoroquinolones are central to TB treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the dose of levofloxacin needed to achieve maximal efficacy and acceptable safety and tolerability as part of a multidrug TB regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Opti-Q was an international, multicenter, randomized, placebo-controlled phase II trial. Eligible participants with TB resistant to isoniazid and rifampicin but susceptible to fluoroquinolones were randomized to receive one of four weight-adjusted once-daily doses of levofloxacin for 24 weeks (168 doses) alongside a multidrug regimen: 11 mg\/kg (750 mg), 14 mg\/kg (750 mg\/1,000 mg), 17 mg\/kg (1,000 mg\/1,250 mg) or 20 mg\/kg (1,250 mg\/1,500 mg). The primary efficacy outcome was time to sputum culture conversion, and the primary safety outcome was grade \u22653 adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 111 participants were randomized from three sites in South Africa and Peru. Eighty-three (75%) had cavities on chest X-ray, 55 (50%) had a smear grading of 3+, and the median body mass index was 20.4 kg\/m2. Median levofloxacin areas under the curve (AUCs)\/minimum inhibitory concentrations were 573, 633, 918, and 1,343 across the four treatment arms. There was no difference in time to culture conversion on solid or liquid media by treatment arm (stratified log-rank P\u2009=\u20090.282), by tertile of AUC\/minimum inhibitory concentration (P\u2009=\u20090.350), or by dose received (P\u2009=\u20090.723); 69.3%, 74.8%, 70.6%, and 78.3% exhibited culture conversion after 8 weeks on solid media, respectively, across the treatment arms; along with 64.6%, 69.5%, 52.6%, and 69.6% on liquid culture. More participants experienced a grade 3\u20135 AE at higher doses (37.0% and 16.0% in the highest and lowest dose groups, respectively; P\u2009=\u20090.042, Cochran-Armitage test for trend) and higher tertiles of AUC (P\u2009=\u20090.011).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As part of a multidrug regimen, doses of levofloxacin &amp;gt;1,000 mg\/d resulted in greater exposures and increased frequency of AEs but did not result in faster time to sputum culture conversion. A dose of 1,000 mg\/d can achieve the target exposure in nearly all adults and was well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202407-1354oc","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:00:38Z","timestamp":1741881638000},"page":"1277-1287","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P. J.","family":"Phillips","sequence":"first","affiliation":[{"name":"UCSF Center for Tuberculosis and"},{"name":"Department of Medicine, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-6979","authenticated-orcid":false,"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Global Health, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-6792","authenticated-orcid":false,"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[{"name":"TASK, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1747-4352","authenticated-orcid":false,"given":"Eduardo","family":"Gotuzzo","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-4453","authenticated-orcid":false,"given":"Debra","family":"Benator","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Washington DC Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Warren","sequence":"additional","affiliation":[{"name":"Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, SAMRC Centre for Tuberculosis, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sikes","sequence":"additional","affiliation":[{"name":"Laboratory Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Lecca","sequence":"additional","affiliation":[{"name":"Socios En Salud Sucursal Per\u00fa, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1665-299X","authenticated-orcid":false,"given":"Neel R.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology, Global Health, and Medicine and Emory\/Georgia Tuberculosis Research Advancement Center, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Streicher","sequence":"additional","affiliation":[{"name":"Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, SAMRC Centre for Tuberculosis, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Dianis","sequence":"additional","affiliation":[{"name":"Westat, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-0970","authenticated-orcid":false,"given":"Kathleen","family":"Eisenach","sequence":"additional","affiliation":[{"name":"TB or NOT TB Consulting, LLC, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D.","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":false,"suffix":"Jr.","given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology, Biostatistics, Global Health, and Medicine, Boston University Schools of Public Health and Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026031105355236400_bib1","article-title":"WHO consolidated guidelines on drug-sensitive tuberculosis treatment","author":"World Health Organization","year":"2022"},{"key":"2026031105355236400_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031105355236400_bib3","article-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2022"},{"key":"2026031105355236400_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019Wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026031105355236400_bib5","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026031105355236400_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"2026031105355236400_bib7","doi-asserted-by":"crossref","first-page":"e00463-19","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cpt.2685","article-title":"Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens","volume":"112","author":"Tanneau","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026031105355236400_bib9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031105355236400_bib10","doi-asserted-by":"crossref","first-page":"EVIDoa2300054","DOI":"10.1056\/EVIDoa2300054","article-title":"Four-month high-dose rifampicin regimens for pulmonary tuberculosis","volume":"2","author":"Jindani","year":"2023","journal-title":"NEJM Evid"},{"key":"2026031105355236400_bib11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026031105355236400_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase 2 clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026031105355236400_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1164\/rccm.201212-2328OC","article-title":"Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis","volume":"188","author":"Ahmad","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105355236400_bib14","article-title":"Clinical management of rifampicin-resistant tuberculosis: updated clinical reference guide","author":"Republic of South Africa Department of Health","year":"2023"},{"key":"2026031105355236400_bib15","doi-asserted-by":"crossref","first-page":"e02516-18","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","article-title":"Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis","volume":"188","author":"Koh","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031105355236400_bib17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1513\/AnnalsATS.201510-690BC","article-title":"Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes","volume":"13","author":"Kang","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026031105355236400_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib19","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026031105355236400_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1378\/chest.117.3.744","article-title":"Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin\/levofloxacin-containing regimens","volume":"117","author":"Yew","year":"2000","journal-title":"Chest"},{"key":"2026031105355236400_bib21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1378\/chest.128.3.1406","article-title":"Levofloxacin treatment of active tuberculosis and the risk of adverse events","volume":"128","author":"Marra","year":"2005","journal-title":"Chest"},{"key":"2026031105355236400_bib22","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","article-title":"Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders","volume":"26","author":"Noel","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2026031105355236400_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13063-017-2292-x","article-title":"An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial","volume":"18","author":"Bouton","year":"2017","journal-title":"Trials"},{"key":"2026031105355236400_bib25","article-title":"WHO treatment guidelines for drug-resistant tuberculosis\u20132016 update","author":"World Health Organization","year":"2016"},{"key":"2026031105355236400_bib26","article-title":"Treatment of tuberculosis: guidelines","author":"World Health Organization","year":"2010"},{"key":"2026031105355236400_bib27","doi-asserted-by":"crossref","first-page":"e00770-18","DOI":"10.1128\/AAC.00770-18","article-title":"Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/bdd.2294","article-title":"Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy","volume":"42","author":"Boonpeng","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"2026031105355236400_bib30","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026031105355236400_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/cid\/ciac511","article-title":"Pharmacokinetic-pharmacodynamic determinants of clinical outcomes for rifampin-resistant tuberculosis: a multisite prospective cohort study","volume":"76","author":"Heysell","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031105355236400_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026031105355236400_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031105355236400_bib34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026031105355236400_bib35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0091270004264643","article-title":"Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings","volume":"44","author":"Noel","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2026031105355236400_bib36","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031105355236400_bib37","doi-asserted-by":"crossref","first-page":"e0068323","DOI":"10.1128\/aac.00683-23","article-title":"Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis","volume":"67","author":"Stemkens","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031105355236400_bib38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/7\/1277\/67295682\/ajrccm_211_7_1277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/7\/1277\/67295682\/ajrccm_211_7_1277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:36:23Z","timestamp":1773221783000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/7\/1277\/8513648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202407-1354oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2024-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}